Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile.
Petrillo A, Fusco R, Petrillo M, Granata V, Delrio P, Bianco F, Pecori B, Botti G, Tatangelo F, Caracò C, Aloj L, Avallone A, Lastoria S. Petrillo A, et al. Among authors: aloj l. Oncotarget. 2017 Jan 31;8(5):8143-8153. doi: 10.18632/oncotarget.14106. Oncotarget. 2017. PMID: 28042958 Free PMC article.
18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.
Avallone A, Aloj L, Pecori B, Caracò C, De Stefano A, Tatangelo F, Silvestro L, Granata V, Bianco F, Romano C, Di Gennaro F, Budillon A, Petrillo A, Muto P, Botti G, Delrio P, Lastoria S. Avallone A, et al. Among authors: aloj l. J Nucl Med. 2019 Nov;60(11):1560-1568. doi: 10.2967/jnumed.118.222604. Epub 2019 Mar 15. J Nucl Med. 2019. PMID: 30877175 Free PMC article. Clinical Trial.
Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F. Lastoria S, et al. Among authors: aloj l. J Nucl Med. 2013 Dec;54(12):2062-9. doi: 10.2967/jnumed.113.119909. Epub 2013 Oct 17. J Nucl Med. 2013. PMID: 24136935 Free article.
Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.
Avallone A, Aloj L, Caracò C, Delrio P, Pecori B, Tatangelo F, Scott N, Casaretti R, Di Gennaro F, Montano M, Silvestro L, Budillon A, Lastoria S. Avallone A, et al. Among authors: aloj l. Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1848-57. doi: 10.1007/s00259-012-2229-2. Epub 2012 Oct 5. Eur J Nucl Med Mol Imaging. 2012. PMID: 23053320 Clinical Trial.
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, Romano C, Giordano P, Lastoria S, Caracò C, de Lutio di Castelguidone E, Palaia R, Daniele G, Aloj L, Romano G, Iaffaioli RV. Nasti G, et al. Among authors: aloj l. Br J Cancer. 2013 Apr 30;108(8):1566-70. doi: 10.1038/bjc.2013.140. Epub 2013 Apr 4. Br J Cancer. 2013. PMID: 23558891 Free PMC article. Clinical Trial.
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).
Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A. Avallone A, et al. Among authors: aloj l. BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875. BMC Cancer. 2014. PMID: 25421252 Free PMC article. Clinical Trial.
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.
Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco' C, Di Gennaro F, Capobianco G, Giovannoni L, Menssen HD, Neri D, Pinto A, Lastoria S. Aloj L, et al. Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77. doi: 10.1007/s00259-013-2658-6. Epub 2014 Jan 17. Eur J Nucl Med Mol Imaging. 2014. PMID: 24435772 Clinical Trial.
100 results